Kyverna Appoints Ritesh Srivastava as Chief Legal and Compliance Officer to Support Commercial Transition
KYTX has more than doubled off its 52-week low of $2.52.
Summary
Kyverna Therapeutics appointed Ritesh Srivastava as Chief Legal and Compliance Officer, a strategic hire as the company transitions to a commercial-stage organization. This follows recent positive clinical data for miv-cel and the initiation of a BLA submission for Stiff Person Syndrome. Srivastava's extensive experience in regulatory compliance, corporate governance, and commercial transactions is critical for navigating the complexities of bringing a new drug to market. He received an inducement grant of options for 260,000 shares, aligning his incentives with the company's future success.
At the time of this announcement, KYTX was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $490.6M. The 52-week trading range was $2.52 to $13.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.